盐酸阿罗洛尔联合沙库巴曲缬沙坦钠治疗心力衰竭的临床研究

Clinical study on aroprolol hydrochloride combined with sacubitril valsartan sodium in treatment of heart failure

目的探讨盐酸阿罗洛尔联合沙库巴曲缬沙坦钠治疗心力衰竭的临床疗效。方法选取2021年5月至2022年4月该院收治的100例心力衰竭患者,按随机数字表法分为A组和B组,各50例。A组采用盐酸阿罗洛尔联合沙库巴曲缬沙坦钠治疗,B组采用沙库巴曲缬沙坦钠治疗。比较2组临床总有效率、不良心血管事件发生率及心功能指标[左室舒张末内径(LVEDD)、左心室射血分数(LVEF)、心排血指数(CI)、每搏心输出量(SV)]、血管内皮功能指标[内皮素-1(ET-1)、肱动脉内皮依赖性舒张功能(FMD)、一氧化氮(NO)、肱动脉非内皮依赖性舒张功能(NMD)]等。结果A组临床总有效率为96.00%,高于B组的80.00%,差异有统计学意义(P<0.05)。治疗后,A组LVEF、SV、CI、NO、FMD、NMD水平高于B组,LVEDD、ET-1水平低于B组,差异有统计学意义(P<0.05)。2组治疗后血清N末端B型利钠肽原、超敏C反应蛋白、组蛋白脱乙酰酶2、分泌型卷曲相关蛋白2水平与治疗前比较,差异有统计学意义(P<0.05),且A组各指标优于B组(P<0.05)。A组不良心血管事件发生率低于B组,差异有统计学意义(P<0.05)。结论盐酸阿罗洛尔联合沙库巴曲缬沙坦钠治疗心力衰竭效果显著,可有效改善心功能,减轻血管内皮功能受损,促进病情恢复,降低不良心血管事件发生率。

Objective To explore the clinical efficacy of aroprolol hydrochloride combined with sacubitril valsartan sodium in the treatment of heart failure.Methods A total of 100 patients with heart failure admitted to the hospital from May 2021 to April 2022 were selected and divided into the group A and the group B according to the random number table method,50 cases in each group.The group A was treated with aroprolol hydrochloride combined with sacubitril valsartan sodium,and the group B was treated with sacubitril valsartan sodium.The total clinical effective rate,incidence of adverse cardiovascular events and cardiac function indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),cardiac index(CI),stroke volume(SV)],vascular endothelial function indexes[endothelin-1(ET-1),brachial artery endothelium-dependent diastolic function(FMD),nitric oxide(NO),brachial artery endothelium-independent diastolic function(NMD)]were compared between the two groups.Results The total clinical effective rate ofthe group A was 96.00%,which was higher than 80.00%of the group B,and the difference was statistically significant(P<0.05).After treatment,the levels of LVEF,SV,CI,NO,FMD and NMD in the group A were higher than those in the group B,and the levels of LVEDD and ET-1 were lower than those in the group B,the differences were statistically significant(P<0.05).After treatment,the levels of serum N-terminal pro-B-type natriuretic peptide,hypersensitive C-reactive protein,histone deacetylase 2,and secretory curl related protein 2 in the two groups were significantly different from those before treatment(P<0.05),and the indexes in the group A were better than those in the group B(P<0.05).The incidence of adverse cardiovascular events in the group A was lower than that in the group B,the difference was statistically significant(P<0.05).Conclusion Aroprolol hydrochloride combined with sacubitril valsartan sodium is effective in the treatment of heart failure,which can effectively improve cardiac function,reduce vascular endothelial function damage,promote disease recovery,and reduce the incidence of adverse cardiovascular events.